[go: up one dir, main page]

MX2017015817A - Anticuerpos de union a tau. - Google Patents

Anticuerpos de union a tau.

Info

Publication number
MX2017015817A
MX2017015817A MX2017015817A MX2017015817A MX2017015817A MX 2017015817 A MX2017015817 A MX 2017015817A MX 2017015817 A MX2017015817 A MX 2017015817A MX 2017015817 A MX2017015817 A MX 2017015817A MX 2017015817 A MX2017015817 A MX 2017015817A
Authority
MX
Mexico
Prior art keywords
tau
binding antibodies
binding
antibodies
relates
Prior art date
Application number
MX2017015817A
Other languages
English (en)
Inventor
Edward Ormonde Knight David
Seward Baker Terence
Anthony Griffin Robert
James MCMILLAN David
Mairet-Coello Georges
Downey Patrick
Philippe Courade Jean-
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53524640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017015817(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MX2017015817A publication Critical patent/MX2017015817A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a anticuerpos de unión a Tau y fragmentos de unión de los mismos.
MX2017015817A 2015-07-06 2016-07-05 Anticuerpos de union a tau. MX2017015817A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15175522 2015-07-06
PCT/EP2016/065813 WO2017005734A1 (en) 2015-07-06 2016-07-05 Tau-binding antibodies

Publications (1)

Publication Number Publication Date
MX2017015817A true MX2017015817A (es) 2018-04-10

Family

ID=53524640

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015817A MX2017015817A (es) 2015-07-06 2016-07-05 Anticuerpos de union a tau.

Country Status (27)

Country Link
US (4) US10287343B2 (es)
EP (1) EP3319983A1 (es)
JP (3) JP6630426B2 (es)
KR (2) KR20250027278A (es)
CN (1) CN107849104B (es)
AR (1) AR105267A1 (es)
AU (1) AU2016289755C1 (es)
BR (1) BR112017028102A2 (es)
CA (1) CA2991451A1 (es)
CL (1) CL2018000043A1 (es)
CO (1) CO2017012971A2 (es)
EA (1) EA037092B1 (es)
EC (1) ECSP18000887A (es)
HK (1) HK1246804A1 (es)
IL (1) IL256685B (es)
MA (2) MA42377A (es)
MX (1) MX2017015817A (es)
MY (1) MY193677A (es)
PE (1) PE20180481A1 (es)
PH (1) PH12017502207B1 (es)
SG (1) SG10202010735PA (es)
TN (1) TN2017000539A1 (es)
TW (1) TWI745295B (es)
UA (1) UA124616C2 (es)
UY (1) UY36773A (es)
WO (1) WO2017005734A1 (es)
ZA (1) ZA201800027B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2732122C2 (ru) 2015-06-05 2020-09-11 Дженентек, Инк. Антитела против тау-белка и способы их применения
BR112017028102A2 (pt) 2015-07-06 2018-09-04 Ucb Biopharma Sprl anticorpos de ligação à tau
BR112017028101A2 (pt) 2015-07-06 2018-09-04 Ucb Biopharma Sprl anticorpos de ligação à tau
CN117820467A (zh) 2016-12-07 2024-04-05 基因泰克公司 抗tau抗体和使用方法
PE20201186A1 (es) 2016-12-07 2020-11-03 Genentech Inc Anticuerpos antitau y metodos de uso
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
CN110520440A (zh) 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
JOP20180014A1 (ar) 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
UA129617C2 (uk) 2017-10-16 2025-06-18 Еісаі Р Енд Д Менеджмент Ко., Лтд. Антитіло до тау та його застосування
EP3894438A1 (en) * 2018-12-13 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
US20220299527A1 (en) * 2019-08-13 2022-09-22 Washington University Methods to detect mtbr tau isoforms and use thereof
EP4103615A1 (en) 2020-02-12 2022-12-21 Eli Lilly and Company Crystallization of antibodies or antigen-binding fragments
US20230265175A1 (en) 2020-06-25 2023-08-24 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
IL319121A (en) 2022-09-15 2025-04-01 Voyager Therapeutics Inc Tau-binding compounds
WO2024107745A1 (en) * 2022-11-14 2024-05-23 Washington University Methods to detect csf mtbr-tau and uses thereof
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
CN101307108B (zh) * 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
BRPI0918947A2 (pt) 2008-09-26 2015-12-01 Ucb Pharma Sa proteína de fusão de anticorpo
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
MX2011005963A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
US20110288009A1 (en) 2008-12-05 2011-11-24 Angiochem Inc. Leptin and leptin analog conjugates and uses thereof
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US20120283415A1 (en) 2009-09-10 2012-11-08 Ucb Pharma S.A. Multivalent Antibodies
JP2013506697A (ja) 2009-10-06 2013-02-28 アンジオケム インコーポレーテッド 治療薬を輸送するための組成物と方法
JP6371526B2 (ja) 2010-10-07 2018-08-08 エーシー イミューン エス．エー． タウを認識するリン酸化部位特異的抗体
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
UA123390C2 (uk) 2011-09-19 2021-03-31 Аксон Ньюросайєнс Сє Терапія і діагностика на основі білків тау-опосередковуваної патології при хворобі альцгеймера
SI2776466T1 (sl) 2011-11-11 2017-12-29 Ucb Biopharma Sprl Protitelesa, ki se vežejo na albumin in njihovi vezavni fragmenti
CN107226863B (zh) 2011-12-20 2021-06-01 詹森生物科技公司 抗PHF-tau抗体及其用途
CN104781278B (zh) * 2012-07-03 2018-06-12 华盛顿大学 针对tau的抗体
GB2507207A (en) 2012-08-16 2014-04-23 Ipierian Inc Treatment of Tauopathies
HUE051320T2 (hu) 2012-12-21 2021-05-28 Biogen Ma Inc Humán anti-TAU antitestek
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
BR112017028102A2 (pt) 2015-07-06 2018-09-04 Ucb Biopharma Sprl anticorpos de ligação à tau
BR112017028101A2 (pt) 2015-07-06 2018-09-04 Ucb Biopharma Sprl anticorpos de ligação à tau

Also Published As

Publication number Publication date
CL2018000043A1 (es) 2018-05-18
WO2017005734A1 (en) 2017-01-12
AR105267A1 (es) 2017-09-20
UY36773A (es) 2017-01-31
PH12017502207A1 (en) 2018-06-11
PE20180481A1 (es) 2018-03-07
IL256685A (en) 2018-03-29
CO2017012971A2 (es) 2018-03-09
CN107849104A (zh) 2018-03-27
IL256685B (en) 2022-02-01
MY193677A (en) 2022-10-25
AU2016289755A1 (en) 2018-01-04
KR20180025962A (ko) 2018-03-09
TN2017000539A1 (en) 2019-04-12
JP2022141689A (ja) 2022-09-29
KR102770650B1 (ko) 2025-02-19
US10287343B2 (en) 2019-05-14
CN107849104B (zh) 2021-08-27
EA037092B1 (ru) 2021-02-04
AU2016289755C1 (en) 2021-08-19
MA42377A (fr) 2018-05-16
US20190284267A1 (en) 2019-09-19
EP3319983A1 (en) 2018-05-16
US20230416350A1 (en) 2023-12-28
TWI745295B (zh) 2021-11-11
TW201713689A (zh) 2017-04-16
ZA201800027B (en) 2019-06-26
AU2016289755B2 (en) 2020-12-03
JP7100008B2 (ja) 2022-07-12
HK1246804A1 (zh) 2018-09-14
KR20250027278A (ko) 2025-02-25
US10889640B2 (en) 2021-01-12
JP6630426B2 (ja) 2020-01-15
JP2018524001A (ja) 2018-08-30
US20180201666A1 (en) 2018-07-19
JP7413448B2 (ja) 2024-01-15
US20210115121A1 (en) 2021-04-22
US11732034B2 (en) 2023-08-22
ECSP18000887A (es) 2018-03-31
SG10202010735PA (en) 2020-11-27
EA201890172A1 (ru) 2018-10-31
JP2020055849A (ja) 2020-04-09
NZ738058A (en) 2021-07-30
PH12017502207B1 (en) 2022-08-10
MA41670A1 (fr) 2018-05-31
UA124616C2 (uk) 2021-10-20
BR112017028102A2 (pt) 2018-09-04
CA2991451A1 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
ECSP18000844A (es) Anticuerpos de unión a tau
ECSP18000887A (es) Anticuerpos de unión a tau
IL265321B1 (en) Cd3 binding antibodies
IL272227A (en) Anti-tigit antibodies
DK3625259T3 (da) Anti-sirpalpha-antistoffer
EP3569709A4 (en) ANTI-GPC3 ANTIBODIES
EP3661558A4 (en) ANTI-IL1RAP ANTIBODIES
HUE042039T2 (hu) Humán CD3 kötõ antitest
DK3332006T5 (da) Hidtil ukendte anti-PD-L1-antistoffer
DK3242892T3 (da) Modificerede april-bindende antistoffer
EP3684806A4 (en) NEW ANTI-CD3EPSILON ANTIBODIES
BR112018010360A2 (pt) fragmentos fab de fator de complemento anti-c1q e utilizações dos mesmos
CL2016001742A1 (es) Anticuerpos anti-baff novedosos
EP3691447A4 (en) ANTI-TRANSTHYRETINE ANTIBODY
DK3606961T3 (da) Garp-tgf-beta-antistoffer
DK3452507T3 (da) Tau-immunoterapi
DK3250593T3 (da) Anti-transthyretin-antistoffer
EP3596126A4 (en) NEW ANTI-TRKB ANTIBODIES
EP3617231A4 (en) ANTI-GPC-1 ANTIBODY
DK3253785T3 (da) Hidtil ukendte egfr-bindingsproteiner
EP3532034A4 (en) ANTI-APOE ANTIBODY
EP3579879A4 (en) ANTI-BODY ANTI-KIR3DL1
DK3484921T3 (da) Anti-IL-22R antistoffer
EP3720492A4 (en) ANTI-RSPO3 ANTIBODIES
EP3604518A4 (en) ANTI-GPR20 ANTIBODY